Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 7% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price fell 7% during trading on Monday . The stock traded as low as $3.22 and last traded at $3.2550. Approximately 7,378,720 shares changed hands during trading, a decline of 59% from the average session volume of 18,182,264 shares. The stock had previously closed at $3.50.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, August 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $8.06.

Recursion Pharmaceuticals Price Performance

The stock has a market capitalization of $1.91 billion, a P/E ratio of -3.42 and a beta of 1.03. The business’s 50 day simple moving average is $3.30 and its two-hundred day simple moving average is $3.35. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The business had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. During the same period in the previous year, the firm earned ($0.41) earnings per share. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.92 earnings per share for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 40,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total value of $158,400.00. Following the completion of the sale, the director owned 6,218,287 shares in the company, valued at $24,624,416.52. This represents a 0.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the transaction, the chief executive officer directly owned 2,175,796 shares in the company, valued at $7,789,349.68. The trade was a 1.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 131,937 shares of company stock worth $478,874. 6.65% of the stock is owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 28.1% in the second quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after acquiring an additional 2,428 shares during the period. Equitable Holdings Inc. increased its holdings in Recursion Pharmaceuticals by 7.1% during the 3rd quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock worth $192,000 after acquiring an additional 2,600 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in Recursion Pharmaceuticals by 1.2% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 232,370 shares of the company’s stock worth $954,000 after purchasing an additional 2,753 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in Recursion Pharmaceuticals by 29.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,706 shares of the company’s stock worth $64,000 after purchasing an additional 2,883 shares in the last quarter. Finally, Ascent Wealth Partners LLC boosted its holdings in Recursion Pharmaceuticals by 11.8% in the 1st quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock valued at $86,000 after purchasing an additional 2,974 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.